Review

Subject Category: Review Article

British Journal of Pharmacology (2007) 152, 594–601; doi:10.1038/sj.bjp.0707379; published online 9 July 2007

The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action

C J Fowler1

1Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden

Correspondence: Professor CJ Fowler, Department of Pharmacology and Clinical Neuroscience, Umeå University, SE-901 87 Umeå, Sweden. E-mail: cf@pharm.umu.se

Received 3 May 2007; Revised 13 June 2007; Accepted 14 June 2007; Published online 9 July 2007.

Top

Abstract

The development of sensitive analytical methods for measurement of endocannabinoids, their metabolites, and related lipids, has underlined the complexity of the endocannabinoid system. A case can be made for an 'endocannabinoid soup' (akin to the inflammatory soup) whereby the net effect of a pathological state and/or a pharmacological intervention on this system is the result not only of changes in endocannabinoid levels but also of their metabolites and related compounds that affect their function. With respect to the metabolism of anandamide and 2-arachidonoylglycerol, the main hydrolytic enzymes involved are fatty acid amide hydrolase and monoacylglycerol lipase. However, other pathways can come into play when these are blocked. Cyclooxygenase-2 derived metabolites of anandamide and 2-arachidonoylglycerol have a number of properties, including effects upon cell viability, contraction of the cat iris sphincter (an effect mediated by a novel receptor), mobilization of calcium and modulation of synaptic transmission. Nonsteroidal anti-inflammatory agents, whose primary mode of action is the inhibition of cyclooxygenase, can also interact with the endocannabinoid system both in vitro and in vivo. Other enzymes, such as the lipoxygenase and cytochrome P450 oxidative enzymes, can also metabolize endocannabinoids and produce biologically active compounds. It is concluded that sensitive analytical methods, which allow for measurement of endocannabinoids and related lipids, should provide vital information as to the importance of these alternative metabolic pathways when the primary hydrolytic endocannabinoid metabolizing enzymes are inhibited.

Keywords:

endocannabinoid, anandamide, 2-arachidonoylglycerol, fatty acid amide hydrolase, monoacylglycerol lipase, cyclooxygenase-2, non-steroidal anti-inflammatory agents, prostaglandin ethanolamide, prostaglandin glycerol ester

Abbreviations:

AA, arachidonic acid; AEA, anandamide (arachidonoylethanolamide); 2-AG, 2-arachidonoylglycerol; AM251, N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide; CB, cannabinoid; COX, cyclooxygenase; FAAH, fatty acid amide hydrolase; ibu-am5, N-(3-methylpyridin-2-yl)-2-(4'-isobutylphenyl)propionamide; MGL, monoacylglycerol lipase; OA, oleic aid; OEA, oleoylethanolamide; PA, palmitic acid; PEA, palmitoylethanolamide; PG, prostaglandin; PG-EA, prostamide (prostaglandin ethanolamide); PG-GE, prostaglandin glycerol ester; PPAR, peroxisome proliferator-activated receptor

Top

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated

Extra navigation

.

naturejobs

natureproducts


ADVERTISEMENT